Standard of Care for Haemophilia A
Pre-clinicalCompletedDevelopment Stage
Severe Hereditary Factor VIII Deficiency Disease Without Inhibitor
Severe Hereditary Factor VIII Deficiency Disease Without Inhibitor, Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor, Haemophilia A
Feb 24, 2020 → Apr 28, 2022
About Standard of Care for Haemophilia A
Standard of Care for Haemophilia A is a pre-clinical stage product being developed by Roche for Severe Hereditary Factor VIII Deficiency Disease Without Inhibitor. The current trial status is completed. This product is registered under clinical trial identifier NCT04165135. Target conditions include Severe Hereditary Factor VIII Deficiency Disease Without Inhibitor, Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor, Haemophilia A.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04165135 | Pre-clinical | Completed |
Competing Products
20 competing products in Severe Hereditary Factor VIII Deficiency Disease Without Inhibitor